Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
14(48%)
Results Posted
0%(0 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_3
7
24%
Ph phase_2
14
48%
Ph phase_1
6
21%

Phase Distribution

6

Early Stage

14

Mid Stage

7

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
6(22.2%)
Phase 2Efficacy & side effects
14(51.9%)
Phase 3Large-scale testing
7(25.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

14

trials recruiting

Total Trials

29

all time

Status Distribution
Active(18)
Completed(3)
Terminated(2)
Other(6)

Detailed Status

Recruiting13
unknown6
Not yet recruiting4
Completed3
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
14
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (22.2%)
Phase 214 (51.9%)
Phase 37 (25.9%)

Trials by Status

unknown621%
completed310%
terminated13%
withdrawn13%
recruiting1345%
active_not_recruiting13%
not_yet_recruiting414%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT07168200Phase 3

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Recruiting
NCT05516914Phase 1

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Completed
NCT04379635Phase 3

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active Not Recruiting
NCT06157827Phase 1

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Recruiting
NCT07111546Phase 2

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Recruiting
NCT07331155Phase 2

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Recruiting
NCT07383116Phase 3

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT07229625Phase 3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Recruiting
NCT07268040Phase 2

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Recruiting
NCT06512051Phase 1

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
NCT04325425Phase 2

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Recruiting
NCT06859775Phase 1

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Recruiting
NCT03255252Phase 2

Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy

Terminated
NCT06087614Phase 2

Dose Escalation Using Hypoxia-adjusted Radiotherapy

Recruiting
NCT06514027Phase 2

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Not Yet Recruiting
NCT04444869Phase 2

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

Recruiting
NCT06380348Phase 3

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not Yet Recruiting
NCT06375109Phase 2

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Not Yet Recruiting
NCT06169904

B7-Family Score in Urothelial Carcinoma

Completed
NCT05738057Phase 2

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
29